Clinical profile and treatment outcome of epilepsy syndromes in children: A hospital-based study in Eastern Nepal

Prakash Poudel1, Shyam Prasad Kafle1, Rita Pokharel2

  • 1Department of Pediatrics and Adolescent Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal.

Epilepsia Open
|March 8, 2021
PubMed

Insights

Diagnosing epilepsy syndromes in children is feasible in resource-limited settings, with West syndrome being most common. Many epilepsy syndromes show good response to pharmacotherapy, though some are pharmaco-resistant.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Global Health

Background:

  • Epilepsy syndrome diagnosis is challenging in resource-limited settings.
  • Effective diagnosis and management are crucial for pediatric neurological care.

Purpose of the Study:

  • To investigate the diagnosis, clinical profile, and treatment outcomes of epilepsy syndromes (ESs) in children within a resource-limited environment.
  • To assess the feasibility of classifying epilepsy syndromes using International League Against Epilepsy guidelines.

Main Methods:

  • A descriptive study conducted in eastern Nepal from 2009 to 2017.
  • Included 768 children (1-17 years) with unprovoked seizures presenting to a pediatric neurology clinic.
  • Diagnosis and classification followed International League Against Epilepsy guidelines.

Main Results:

  • 15.6% of children were diagnosed with specific epilepsy syndromes.
  • West syndrome (26.7%) was the most common, followed by generalized tonic-clonic seizures alone (21.7%).
  • Pharmacotherapy showed good response in syndromes like GTCSA, SLFIE, CAE, SLCECTS, GEFS+, and JME, but was less effective for PME, LGS, and WS.

Conclusions:

  • Epilepsy syndromes can be classified in resource-limited settings, with West syndrome being prevalent.
  • Electro-clinical diagnosis can sometimes obviate the need for neuroimaging.
  • Tailored treatment strategies are essential, considering the varying pharmacosensitivity of different epilepsy syndromes.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
814
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
908
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
380
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
598
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
423